GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » COGS-to-Revenue

Nutriband (Nutriband) COGS-to-Revenue : 0.66 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nutriband COGS-to-Revenue?

Nutriband's Cost of Goods Sold for the three months ended in Jan. 2024 was $0.34 Mil. Its Revenue for the three months ended in Jan. 2024 was $0.53 Mil.

Nutriband's COGS to Revenue for the three months ended in Jan. 2024 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nutriband's Gross Margin % for the three months ended in Jan. 2024 was 34.48%.


Nutriband COGS-to-Revenue Historical Data

The historical data trend for Nutriband's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband COGS-to-Revenue Chart

Nutriband Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only 1.48 0.67 0.65 0.64 0.59

Nutriband Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.53 0.54 0.63 0.66

Nutriband COGS-to-Revenue Calculation

Nutriband's COGS to Revenue for the fiscal year that ended in Jan. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.223 / 2.085
=0.59

Nutriband's COGS to Revenue for the quarter that ended in Jan. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.344 / 0.525
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutriband  (NAS:NTRB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Nutriband's Gross Margin % for the three months ended in Jan. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.344 / 0.525
=34.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Nutriband COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nutriband's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutriband (Nutriband) Business Description

Traded in Other Exchanges
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401